• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adding daratumumab increases progression free survival in multiple myeloma

byNeil D'SouzaandShaidah Deghan, MSc. MD
October 6, 2016
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The addition of daratumumab to standard therapy of lenalidomide and dexamethasone increased progression-free survival in relapsed or refractory multiple myeloma (MM).

2. Daratumumab was associated with a greater rate of infusion-related reactions and neutropenia compared to standard therapy alone.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While the addition of proteasome inhibitors and immune modulators have improved outcomes for patients with MM, eventually relapse occurs. Prior phase1-2 trials with daratumumab (IgG monoclonal antibody targeting CD38) have shown improved response rates in patients with pre-treated relapsed or refractory MM using lenalidomide and dexamethasone. Given these results, this trial randomized daratumumab added to lenalidomide and dexamethasone, versus the latter two alone. The results showed a significant increase in disease-free survival, overall response and complete response or better in the daratumumab group compared to the standard group. However, there were more grade 3 or 4 adverse events in terms of neutropenia in the daratumumab group, as well as infusion related reactions compared to the control group. Nevertheless, these adverse events did not lead to higher death or treatment cessation rates. The major strengths of this trial were the large study numbers and randomization across multiple centers, and it built upon prior trials that demonstrated the added benefit of daratumumab. The main limitation was the lack of long-term data.

Click to read the study, published today in NEJM

Relevant Reading: Targeting CD38 with daratumumab monotherapy in multiple myeloma

RELATED REPORTS

Talquetamab and teclistamab combination improved response in relapsed multiple myeloma

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients

In-Depth [randomized controlled trial]: This study randomized 569 patients with MM, who had prior treatment with one or more lines of therapy, to either lenalidomide and dexamethasone alone (control group) or combination with daratumumab (daratumumab). The primary endpoint was progression-free survival.

Of the 569 patients enrolled in the trial, 286 were assigned to the daratumumab group and 283 to the control group. At the median follow-up time point of 13.5 months, there was a total of 169 events of disease progression or death, with 53 (18.5%) in the daratumumab group and 116 (41%) in the control group, for a HR of 0.37 (95%CI 0.27-0.52, p < 0.001). The progression-free survival at 12 months was 83.2% (95%CI 78.3-87.2) in the daratumumab group and 60.1% (95%CI 54-65.7) in the control group. The overall response rate that could be evaluated was 92% in the daratumumab group versus 76.4% in the control group (p < 0.001). In the daratumumab group, 51.9% of patients had grade 3 or 4 neutropenia, compared to 37% in the control group. Thrombocytopenia of grade 3 or 4 occurred in 12.7% of the treatment group and 13.5% of patients in the control group. The incidence of daratumumab infusion-related reaction of any grade was 47.7%, which included cough (8.5%), dyspnea (8.55%) and vomiting (5.7%).

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: multiple myeloma
Previous Post

Higher risk of type 2 diabetes associated with LDL-C-lowering genetic variants

Next Post

Overview of the 2014 measles outbreak in Ohio

RelatedReports

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor
Chronic Disease

Talquetamab and teclistamab combination improved response in relapsed multiple myeloma

March 6, 2025
#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma
StudyGraphics

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

December 26, 2024
Phase III trial shows survival benefit for early multiple myeloma
Pharma

Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients

October 22, 2024
#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone
StudyGraphics

#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone

August 16, 2024
Next Post
Significant percentage of pediatricians dismiss families who refuse vaccines

Overview of the 2014 measles outbreak in Ohio

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Quality in 30-day post-MI mortality linked to increased life expectancy

Ear infections decreasing in infants

Nonparental childcare attendance not linked to obesity

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Food compounds associated with disease activity in inflammatory bowel disease 
  • Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts
  • Volumetric diet and time-restricted eating demonstrate similar outcomes for weight reduction
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.